If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
However, some in the Japanese archaeological community remain skeptical about the presence of cattle in Japan during the Yayoi period, and there is a persistent view that they were brought to Japan from the Korean peninsula by the toraijin, a group of people who came to Japan in the mid-5th century during the Kofun period. At the Nango-Ōhigashi site in Gose City, Nara Prefecture, excavations revealed cow bones believed to date back to the 5th century. At the Funamiya Kofun Tumulus (late 5th century) in Asago City, Hyōgo Prefecture, pieces of a cow-shaped haniwa (clay figurine), believed to be the oldest in Japan, have been excavated. In addition, a cow-shaped haniwa was excavated from the Hashida No. 1 Tumulus in Tawaramoto Town, Shiki-gun, Nara Prefecture in the first half of the 6th century, and was designated as an Important Cultural Property of Japan in 1958. On the other hand, recent genetic studies have shown that Wagyu and Korean cattle (Hanwoo and others) differ greatly in their genetic information. Livestock cattle are divided into two major lineages: northern lineage cattle (Bos taurus) and Indian lineage cattle (Bos indicus), and both Wagyu and Korean cattle belong to the northern lineage and do not contain Indian lineage such as Zebu cattle. However, in terms of mitochondrial DNA haplogroups, haplogroup T4 (East Asian type) is predominant in the Wagyu (Japanese Black) at about 65%, while haplogroup T3 (European type) is predominant in Korean cattle at 66–83%.
== Genes == The gene for the alpha subunit is located on chromosome 6q12.21. The luteinizing hormone beta subunit gene is localized in the LHB/CGB gene cluster on chromosome 19q13.32. In contrast to the alpha gene activity, beta LH subunit gene activity is restricted to the pituitary gonadotropic cells. It is regulated by the gonadotropin-releasing hormone from the hypothalamus. GnRH activates Egr1 which interacts with transcription factors NR5A1 and PITX1 at the gene promoter to up-regulate LHB transcription.
== Degradation mechanism == PLGA degradation is mainly governed by bulk erosion rather than surface erosion, specifically in microspheres and implants. Water penetration throughout the polymer matrix in these systems results in homogeneous hydrolysis of its ester linkages, leading to a progressive decrease in molecular weight before significant loss of mass occurs. It has been shown that the time required for degradation of PLGA is related to the monomers' ratio used in production: the higher the content of glycolide units, the lower the time required for degradation as compared to predominantly lactide materials. An exception to this rule is the copolymer with 50:50 monomers' ratio which exhibits the faster degradation (about two months). In addition, polymers that are end-capped with esters (as opposed to the free carboxylic acid) demonstrate longer degradation half-lives. This flexibility in degradation has made it convenient for fabrication of many medical devices, such as, grafts, sutures, implants, prosthetic devices, surgical sealant films, micro and nanoparticles. Degradation behavior is also influenced by factors like polymer composition, molecular weight, pH, ionic strength, etc. This process is usually accompanied by the formation of an acidic environment within the polymer matrix due to the accumulation of lactic and glycolic acid degradation products, which can further accelerate autocatalytic degradation. Limited diffusion of acidic byproducts can lead to localized pH gradients and heterogeneous degradation within larger PLGA systems.
== Awards and honors == The Indian Academy of Sciences elected Rao as their fellow in 1993 and he became a fellow of the National Academy of Sciences, India, the next year. The Council of Scientific and Industrial Research awarded him the Shanti Swarup Bhatnagar Prize, one of the highest Indian science awards, in 1997 and he received the National Bioscience Award for Career Development in 1999. He was elected by the Indian National Science Academy as a fellow in 2000, the same year as he received the Millennium Plaque of Honour of the Indian Science Congress. He is also a recipient of the Ranbaxy Research Award which he received in 2001.
== Description == All Artocarpus species are laticiferous trees or shrubs that are composed of leaves, twigs and stems capable of producing a milky sap. The flora type is monoecious and produces unisexual flowers; furthermore, both sexes are present within the same plant. The plants produce small, greenish, female flowers that grow on short, fleshy spikes. Following pollination, the flowers grow into a syncarpous fruit, and these are capable of growing into very large sizes. The stipulated leaves vary from small and entire (Artocarpus integer) to large and lobed (Artocarpus altilis), with the cordate leaves of the species A. altilis ending in long, sharp tips.
Sources: en.wikipedia.org
=== Drying === Once the gelation is completed, the liquid surrounding the silica network is carefully removed and replaced with air, while keeping the aerogel intact. It is crucial that the gel is dried in such a way as to minimize the surface tension within the pores of the solid network. This is typically accomplished through supercritical fluid extraction using supercritical carbon dioxide (scCO2) or freeze-drying.This section briefly describes and compares the processing strategies of supercritical drying and freeze-drying. Gels where the liquid is allowed to evaporate at a natural rate are known as xerogels (i. e. are not aerogels). As the liquid evaporates in such manner, forces caused by surface tensions of the liquid-solid interfaces are enough to destroy the fragile gel network. As a result, xerogels cannot achieve the high porosities and instead peak at lower porosities and exhibit large amounts of shrinkage after drying. To avoid the collapse of fibers during slow solvent evaporation and reduce surface tensions of the liquid-solid interfaces, aerogels can be formed by lyophilization (freeze-drying). Depending on the concentration of the fibers and the temperature to freeze the material, the properties such as porosity of the final aerogel will be affected. In 1931, to develop the first aerogels, Kistler used a process known as supercritical drying which avoids a direct phase change.
=== Policies === According to World Health Organization, policymakers can help tackle resistance by strengthening resistance-tracking and laboratory capacity and by regulating and promoting the appropriate use of medicines. Policymakers and industry can help tackle resistance by: fostering research and development of new tools and promoting cooperation and information sharing among all stakeholders.
== Contraindications == Like other AASs, oxandrolone may worsen hypercalcemia by increasing osteolytic bone resorption. When taken by pregnant women, oxandrolone may have unintended effects such as masculinization on the fetus.
For example, the IRGC's involvement in border controls and critical transportation hubs, such as airports, allows it to bypass customs regulations, importing goods illicitly to maintain its economic advantage. This behavior often destabilizes local markets and contributes to food insecurity, as the organization's financial interests may not align with public needs. These activities highlight the IRGC's transition from a military and security body to a comprehensive socio-economic entity within Iran, wielding significant power over critical resources, including the food supply chain.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.